Piqray
Novartis Pharmaceuticals
Piqray is a pharmaceutical agent made for postmenopausal women and men with a PIK3CA mutation in HR+, HER2- metastatic breast cancer whose disease has progressed on or after endocrine therapy.
It is designed to be used in combination with the medicine fulvestrant in people who have gone through menopause and who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer or breast cancer that has spread to other parts of the body (metastatic), with an abnormal phosphatidylinositol-3-kinase catalytic subunit alpha (PIK3CA) gene.
Common side effects associated with Piqray include rash, nausea, tiredness and weakness, decreased appetite, mouth sores, vomiting, Weight loss, hair loss and changes in certain blood tests.
Next >>
Filed Under: Drug Discovery, Drug Discovery and Development, Neurological Disease, Oncology, Orphan Drugs
